X @Bloomberg

Regulatory Approval - Replimune shares surged following US regulators' acceptance of its resubmitted application for a skin cancer treatment [1] - The acceptance suggests a potential reversal of a previous denial [1] Company Focus - Replimune is developing a treatment for skin cancer [1]